Slava technopark resident participates in clinical trials of nasal COVID vaccine
The Exacte Labs Research Center (a technopark resident), together with the pharmaceutical company GENERIUM, have started phase II-III clinical trials of the GNR-099 combined nasal vector vaccine against coronavirus.
1,320 volunteers will take part in a double-blind, randomized clinical trial of the safety and immunogenicity of the drug, according to data from the state registry of permits for clinical trials.
The clinical trial of the nasal vaccine is taking place at six Moscow polyclinics: No. 2, 36, 52, 68, 115 and 210, as well as eleven centers throughout Russia - Nizhny Novgorod, St. Petersburg, Saransk, Saratov, Smolensk and Yaroslavl.
Polyclinics have already received the new vaccine in the form of a spray and have started working with Muscovites who want to take part in the study. For its implementation, special blocks have been created, consisting of several rooms. Under the terms of the study, all healthy citizens between the ages of 18 and 60 can become volunteers. They must not have been vaccinated against COVID-19, have not been ill with coronavirus for six months, and not have been in contact with someone infected with COVID-19 in the last 14 days. All this should confirm the screening through which each volunteer must go through before he is allowed to test.
During the study, the immunogenicity and safety of the vaccine will be compared with those of Gam-Kovid-Vak. The study is scheduled to be completed by December 31, 2023.
70 innovative companies in the field of biomedicine, instrumentation, IT and energy technologies work in the Moscow technopark Slava. They employ over a thousand people.
